New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Distributed on behalf of Conavi Medical.

Hospitals are now aggressively treating heart disease and other conditions with procedures that require less invasive tools. In fact, that shift is creating greater demand for imaging technology that helps them see where they’re working, creating opportunities for companies such as Conavi Medical (TSXV: CNVI) (OTCQB: CNVIF), Philips (NYSE: PHG), Boston Scientific (NYSE: BSX), Terumo (OTC: TRUMY), and Abbott Laboratories (NYSE: ABT).

For instance, Conavi’s next-generation, FDA-cleared imaging system combines two technologies: intravascular ultrasound (IVUS) and optical coherence tomography (OCT). Together, they give cardiologists a more detailed look inside the arteries that supply blood to the heart. It also allows doctors to examine blockages, assess plaque and calcium buildup, and measure the area that needs treatment. All of which helps them choose the right size stent and decide how to prepare the artery before inserting it.

The company received FDA 510(k) clearance for its next-generation hybrid imaging system. Peer-reviewed research showed how hybrid imaging can help guide coronary treatment decisions. The company also reported its first U.S. commercial placement of OCTIV, benefits in early cases, and continued use by multiple physicians. It extended its Japan Lifeline credit facilities by five years, to April 2032.

Here’s more from Conavi Medical’s (TSXV: CNVI) (OTCBQ: CNVIF) President and CEO

Conavi Medical a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today issued the following letter to shareholders from Thomas Looby, President and Chief Executive Officer.

Dear Shareholders,

Years of development have now translated into U.S. commercial clinical use. Over the past year, Conavi achieved four milestones that establish the foundation for OCTIV™, powered by Novasight™:

· FDA 510(k) clearance for our next-generation hybrid imaging system.

· Peer-reviewed clinical evidence illustrating how hybrid imaging can inform coronary treatment decisions.

· First U.S. commercial placement and clinically beneficial cases with OCTIV, followed by ongoing use by multiple physicians.

· Five-year extension of the Japan Lifeline credit facilities, moving maturity from April 2027 to April 2032.

Together, these achievements position Conavi to broaden physician adoption, expand hospital placements, grow recurring catheter utilization and attract strategic interest in our platform.

Clinical Evidence Supports Broader Adoption

OCTIV combines the imaging depth of intravascular ultrasound with the high-resolution detail of optical coherence tomography in a single catheter to guide coronary interventions.

The 2025 U.S. acute coronary syndrome guidelines give IVUS or OCT a Class 1, Level of Evidence A recommendation for procedural guidance in patients with acute coronary syndromes undergoing stent implantation in the left main artery or complex lesions. Pooled randomized evidence shows lower risks of cardiac death, heart attacks, repeat interventions and stent thrombosis with intravascular imaging guidance than with angiography alone.

Our peer-reviewed case reports illustrate how hybrid imaging can inform treatment decisions:

· July case report. In the Journal of the Society for Cardiovascular Angiography & Interventions, physicians described using hybrid imaging to assess and treat a calcified lesion in a patient with impaired renal function, with IVUS-only imaging at selected stages helping to limit contrast exposure.

· September case report. In Catheterization and Cardiovascular Interventions, hybrid imaging helped physicians evaluate post-stent dissections and white thrombus, informing decisions on further stenting and medical management.

OCTIV Is in Ongoing Clinical Use

In November, we announced our first U.S. commercial placement and clinical cases, with Dr. Megha Prasad performing the initial cases. Approximately 25 clinical cases have been completed within the first two weeks of launch. Successful cases are continuing, with multiple physicians on the hospital's team now using OCTIV.

OCTIV incorporates enhancements focused on image quality, catheter deliverability and ease of use. Its patient interface module sits outside the sterile field, and the catheter connection workflow is designed to simplify setup.

Strong Physician Demand Following Launch and TCT

Following our first U.S. clinical cases, we participated in Transcatheter Cardiovascular Therapeutics 2026, where OCTIV received a strong reception. Clinical presentations and physician education sessions introduced its complementary imaging capabilities to a broader audience.

Demand for OCTIV systems now exceeds our current placement capacity. The response to our limited market release and initial clinical experience, as well as discussions at TCT have surfaced strong demand for OCTIV systems. We will work to meet this demand over time.

We also presented preclinical saline-based imaging results: 26 interpretable imaging pullbacks in three swine, without iodinated contrast during image acquisition. These findings support further evaluation of an approach that could help physicians manage contrast exposure.

Financial Flexibility Supports Commercial Expansion

· Japan Lifeline support. Backed by a relationship spanning more than a decade, the five-year extension better aligns our debt maturity with our commercial development plans.

· $1.75 million received under Ontario's Life Sciences Scale-Up Fund, including a $1.25 million payment following FDA clearance. The agreement provides up to $2.5 million, subject to specified milestones, for eligible commercialization and manufacturing activities.

Our spending priorities are physician support, additional sites, reliable product supply and clinical evidence.

Clear Priorities for Growth

Our first U.S. placement and ongoing clinical cases are meeting and exceeding our expectations. Our priority now is to supply this strong, initial demand through carefully selected hospital placements, physician education and support for repeat use. Four priorities will guide our execution:

· Prioritize the next U.S. placements. Focus on hospitals where physician demand, procedural needs and operational readiness align.

· Grow catheter utilization. Build on ongoing use at our first U.S. site by supporting repeat procedures and training additional physicians.

· Generate clinical evidence. Build on our initial commercial cases and peer-reviewed reports to support further publications showing how hybrid imaging informs treatment decisions.

· Expand physician education and market awareness. Follow up on TCT discussions with targeted education, scientific meetings and direct engagement to help interested clinical teams integrate OCTIV into their workflows.

Building a Sustainable Commercial Business

This year, the essential pieces came together: regulatory clearance, published clinical evidence, ongoing U.S. commercial use and greater financial flexibility. We now have a clear foundation for growth.

We believe disciplined execution can strengthen Conavi's commercial position, attract strategic interest in our platform and create lasting shareholder value. To our employees, clinical collaborators, partners and shareholders, thank you for helping bring Conavi to this point. We look forward to sharing our progress as we expand OCTIV's clinical and commercial reach.

Other related developments from around the markets include:

Philips, a global leader in health technology, today announced U.S. commercial availability of the HyperVue Integrated System [1], a new single room-based configuration of its HyperVue Imaging System for DeepOCT+NIRS imaging and X1-FFR physiology assessment. It is designed to keep advanced coronary imaging and physiology tools connected and readily available in the interventional suite. The system will be showcased at TCT 2026 in San Diego, California, October 31–November 3, alongside Philips’ broader portfolio of imaging, physiology and procedural guidance solutions for precision PCI. “Every procedure is an opportunity to help a patient return to a fuller life, and physicians need technology that supports confident clinical decisions without adding unnecessary complexity or time,” said Stacy Beske, Business Leader, Image Guided Therapy Devices at Philips. “For advanced intravascular imaging to become part of everyday practice, it has to fit naturally into the high-volume workflow of the interventional suite. Part of what Philips will showcase at TCT is how this approach extends across our portfolio, bringing imaging, physiology and procedural guidance closer together so physicians can access the information they need throughout the PCI procedure.”

Boston Scientific announced positive six-month primary endpoint results from the SIMPLAAFY randomized controlled trial of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device. The study evaluated two single-drug regimens as alternatives to dual anti-platelet therapy (DAPT) following implantation of the device in patients with non-valvular atrial fibrillation (NVAF). Key results were presented as a late-breaking clinical trial at Transcatheter Cardiovascular Therapeutics® (TCT®) 2026, the annual scientific symposium of the Cardiovascular Research Foundation® (CRF®) and simultaneously published in JAMA. The WATCHMAN FLX Pro device used in the trial is intended to protect against strokes caused by blood clots that form in the left atrial appendage (LAA) in people with NVAF who need an alternative to long-term blood thinners, and includes HEMOCOAT Technology™, which is designed to enable more controlled, faster healing following implantation. The SIMPLAAFY trial is assessing whether the device, with the addition of HEMOCOAT, may continue to offer similar rates of stroke protection and reduce early bleeding when paired with less-intensive post-implant regimens, and will follow patients through 12 months.

Terumo, and the University of Oxford have established a six-year strategic research collaboration to advance organ perfusion technologies and explore new applications in transplantation and patient-connected therapies. As part of this collaboration, Terumo will provide over $9m USD of financial support, access to proprietary technology and world-leading expertise in medical device development to support a major Oxford research program exploring advances in transplantation and future patient-connected therapeutic technologies. The collaborative research program brings together researchers from Oxford's Medical Sciences and Mathematical, Physical and Life Sciences Divisions with Terumo's strengths in product development, manufacturing, and bringing healthcare innovations to patients around the world. The program aims to expand the use of organ perfusion technologies beyond their established role in transplantation and explore how they might support new approaches to treatment development and delivery. The collaboration further strengthens the relationship between the University of Oxford and Terumo, building on the momentum created by Terumo’s acquisition of OrganOx in 2025.

Abbott Laboratories, the global healthcare leader, announced today it has initiated the VOYAGER CE clinical trial evaluating the safety and efficacy of its investigational Encantor™ transcatheter aortic valve implantation (TAVI) software-guided balloon-expandable system for treating symptomatic severe aortic stenosis. The first enrollment in the VOYAGER CE study occurred at Macquarie University in Sydney, Australia, led by Stephen Worthley, M.B.B.S, Ph.D. The prospective, single-arm, pre-market study will enroll up to 300 patients in Europe and Australia with symptomatic severe aortic stenosis caused by severe calcium buildup in the aortic valve. The study will be the basis to seek approval for use in Europe and Australia. "TAVI has transformed the treatment of severe aortic stenosis, but physicians continue to seek technologies that make procedures more predictable and allow treatment to be tailored to individual patients," said Didier Tchétché, M.D., director of the structural heart disease department, Clinique Pasteur, Toulouse, France, and co-principal investigator of VOYAGER CE. "Encantor's balloon-expandable design and software-guided approach are intended to give physicians greater control and procedural confidence."

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Conavi Medical. by Conavi Medical. We own ZERO shares of Conavi Medical. Winning Media and its principals participated in a financing of the issuer and currently beneficially own seven hundred five thousand one hundred freely tradable shares. Winning Media and/or its principals may sell some or all of these shares in the open market at any time, which could negatively impact the issuer’s share price. Please click here for full disclaimer.

Contact:

Ty Hoffer

Winning Media

281.804.7972

[email protected]